. . "Peror\u00E1ln\u00ED pod\u00E1n\u00ED.\nObvykl\u00E1 d\u00E1vka je jedna tableta p\u0159\u00EDpravku Gleperil Combi 2 mg/0.625 mg jednou denn\u011B, pokud mo\u017Eno u\u017E\u00EDvan\u00E1 r\u00E1no a p\u0159ed j\u00EDdlem. D\u00E1vka by m\u011Bla b\u00FDt individu\u00E1ln\u011B upravena dle profilu pacienta a m\u00EDry poklesu krevn\u00EDho tlaku jako odezvy na pod\u00E1n\u00ED p\u0159\u00EDpravku. Pokud se uk\u00E1\u017Ee tato d\u00E1vka pro \u00FApravu krevn\u00EDho tlaku nedostate\u010Dn\u00E1, m\u016F\u017Ee b\u00FDt zv\u00FD\u0161ena na Gleperil Combi 4 mg/1.25 mg jednou denn\u011B.\nJe-li to z\u00A0klinick\u00E9ho hlediska vhodn\u00E9, je mo\u017En\u00FD p\u0159\u00EDm\u00FD p\u0159echod z\u00A0monoterapie perindoprilem na Gleperil Combi. V\u00A0takov\u00E9m p\u0159\u00EDpad\u011B m\u016F\u017Ee b\u00FDt pot\u0159ebn\u00E1 individu\u00E1ln\u00ED titrace d\u00E1vky.\nStar\u0161\u00ED pacienti (viz bod 4.4)\nL\u00E9\u010Dba by m\u011Bla b\u00FDt zah\u00E1jena d\u00E1vkou 2 mg/0,625 mg denn\u011B s ohledem na odpov\u011B\u010F krevn\u00EDho tlaku a ren\u00E1ln\u00EDch funkc\u00ED.\nPacienti s\u00A0ren\u00E1ln\u00ED insuficienc\u00ED (viz bod 4.3.a 4.4)\nL\u00E9\u010Dba je kontraindikov\u00E1na v p\u0159\u00EDpad\u011B t\u011B\u017Ek\u00E9 ren\u00E1ln\u00ED insuficience (clearance kreatininu pod 30 ml/min). \nU pacient\u016F se st\u0159edn\u011B t\u011B\u017Ekou\u00A0ren\u00E1ln\u00ED insuficienc\u00ED (clearance kreatininu 30 - 60 ml/min) se doporu\u010Duje zah\u00E1jit l\u00E9\u010Dbu vhodnou d\u00E1vkou kombinovan\u00E9 l\u00E9\u010Dby.\nU pacient\u016F s\u00A0clearance kreatininu 60 ml/min a vy\u0161\u0161\u00ED nen\u00ED nutn\u00E1 \u00FAprava d\u00E1vkov\u00E1n\u00ED. \nV b\u011B\u017En\u00E9 l\u00E9ka\u0159sk\u00E9 praxi se prov\u00E1d\u00ED pravideln\u00E1 kontrola kreatininu a drasl\u00EDku. \nPacienti s\u00A0jatern\u00ED insuficienc\u00ED (viz bod 4.3, a 4.4)\nU z\u00E1va\u017En\u00E9 jatern\u00ED insuficience je l\u00E9\u010Dba kontraindikov\u00E1na.\nU pacient\u016F se st\u0159edn\u011B z\u00E1va\u017Enou jatern\u00ED insuficienc\u00ED nen\u00ED pot\u0159eba \u00FApravy d\u00E1vkov\u00E1n\u00ED.\nD\u011Bti a dosp\u00EDvaj\u00EDc\u00ED:\nP\u0159\u00EDpravek Gleperil Combi by se nem\u011Bl pou\u017E\u00EDvat u d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch, proto\u017Ee \u00FA\u010Dinnost a sn\u00E1\u0161enlivost perindoprilu u d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch, samotn\u00E9ho nebo v\u00A0kombinaci, nebyla stanovena. \n"@cs . . . . . "004.002" . "4.2\tD\u00E1vkov\u00E1n\u00ED a zp\u016Fsob pod\u00E1n\u00ED"@cs . . . . . . .